Connect with Abzena’s AOC development and manufacturing experts at our tabletop at the upcoming PBSS workshop in Cambridge, MA, on Sept. 9th to learn how our integrated approach is de-risking the development path to IND and beyond.

Workshop title: IND Filing and Nonclinical Considerations for Emerging Modalities: Protein Degraders, Oral Peptides, and Oligonucleotide

Workshop Overview

Developing IND-enabling packages for novel therapeutic modalities such as protein degraders, oral peptides, and oligonucleotide conjugates presents increasing scientific complexity. These modalities often break from traditional nonclinical paradigms due to unique pharmacokinetic properties, tissue distribution, metabolism, and potential off-target effects. This workshop is structured to provide an overview of nonclinical strategies, with a particular emphasis on pharmacokinetics and toxicology considerations for these emerging modalities. Industry experts will discuss pragmatic approaches, development strategies, and case studies to address modality-specific challenges and support successful IND filings.

Speakers include:

• Alexa (Murray) Rizzolo from BMS
• Ruchia Duggal from Merck
• Thomas von Erlach from Vivtex
• Husain Attarwala from Aera Therapeutics
• Jeff Kurz from Alnylam

Schedule a Meeting